Palo Alto Investors LP
CIK 1306923 · Lihat di SEC EDGAR ↗
- Nilai Portofolio
- $723.7M
- Posisi
- 52
- Per tanggal
- 30 Juni 2026
#3.025 dari 9.443 berdasarkan nilai 13F · top 32.0%
Nilai portofolio QoQ: +10.7% 13F tidak mengungkapkan kas
- Bobot 10 kepemilikan teratas
- 61,28%
- Bobot 25 kepemilikan teratas
- 91,65%
- Posisi di atas 1%
- 26
- Jumlah posisi efektif
- 20,4
Berdasarkan kepemilikan ekuitas jangka panjang 13F saja (kas, obligasi, posisi jual tidak diungkapkan)
Perputaran Q2 2026: 4,79% Perkiraan pembelian $32.983.630 · penjualan $38.290.648
Kepemilikan median: 5,0 kuartal Dilacak Q4 2024–Q2 2026 · 72,2% masih dipegang
- Posisi baru
- 3
- Meningkat
- 5
- Menurun
- 15
- Tertutup
- 2
Di halaman ini
- Kinerja vs S&P Bagaimana portofolio 13F manajer ini berkinerja terhadap S&P 500.
- Rincian sektor Bagaimana portofolio terbagi di berbagai sektor pasar.
- Portofolio Setiap saham yang dilaporkan dimiliki oleh institusi ini, dari 13F terbarunya.
- Taruhan Bernilai Tinggi Kepemilikan yang paling terkonsentrasi pada manajer ini.
- Taruhan baru terbesar Posisi baru yang dibuka pada kuartal terakhir.
- Pergerakan Teratas Peningkatan dan penurunan posisi terbesar pada kuartal ini.
- Posisi yang keluar Posisi yang sepenuhnya dijual oleh manajer pada kuartal lalu.
- Terkait Orang di balik pengaju ini, jika kami dapat mencocokkannya.
Kinerja vs S&P 500
Tahunan: +31.3% · S&P 500: +18.0%
Perkiraan portofolio beli-dan-tahan yang dibangun dari snapshot 13F SEC triwulanan. Mengecualikan kas, posisi jual, opsi/derivatif, dan sekuritas non-13(f) — mencerminkan buku ekuitas long yang diungkapkan saja, bukan total AUM dana. Keterlambatan pengajuan SEC hingga 45 hari; ini bukan waktu yang dapat disalin secara real-time.
Cakupan yang dapat dihargai: 98,9% · Opsi dikecualikan: 0,0%
Rincian sektor
Healthcare
98,0%
Financials
0,3%
Lainnya/Tidak terpetakan
1,7%
Portofolio lengkap 52 posisi
| Tipe | Rentetan | Tren 8 kuartal | |||||
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics, Inc. - Common Stock | $74.950.268 | 10,36% | 918.846 | $12.161.183 | Turun ×1 | ||
| ACAD ACADIA Pharmaceuticals Inc. - Common Stock | $72.461.629 | 10,01% | 2.864.096 | $8.515.438 | Turun ×1 | ||
| INSM Insmed Incorporated - Common Stock | $44.138.548 | 6,10% | 413.980 | $-23.766.239 | Turun ×6 | ||
| MIRM Mirum Pharmaceuticals, Inc. - common stock | $40.834.953 | 5,64% | 348.808 | $10.795.286 | Naik ×3 | ||
| ANAB AnaptysBio, Inc. - Common Stock | $40.735.508 | 5,63% | 603.489 | $5.343.099 | Turun ×2 | ||
| BMRN BioMarin Pharmaceutical Inc. - Common Stock | $39.068.500 | 5,40% | 682.777 | $362.569 | Turun ×6 | ||
| DYN Dyne Therapeutics, Inc. - Common Stock | $36.591.441 | 5,06% | 1.647.521 | $6.623.059 | Turun ×1 | ||
| UTHR United Therapeutics Corporation - Common Stock | $33.911.514 | 4,69% | 62.587 | $-3.332.967 | Turun ×1 | ||
| IRON Disc Medicine, Inc. - Common Stock | $30.473.488 | 4,21% | 416.646 | $4.787.575 | Naik ×4 | ||
| BIIB Biogen Inc. - Common Stock | $30.308.681 | 4,19% | 140.279 | $4.510.667 | Turun ×4 | ||
| IOVA Iovance Biotherapeutics, Inc. - Common Stock | $22.032.229 | 3,04% | 5.296.209 | $-254.737 | Turun ×3 | ||
| RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $19.916.968 | 2,75% | 596.495 | $7.420.398 | |||
| NVCR NovoCure Limited - Ordinary Shares | $19.398.651 | 2,68% | 1.280.439 | $5.441.866 | |||
| SNDX Syndax Pharmaceuticals, Inc. - Common Stock | $18.908.594 | 2,61% | 864.986 | $-1.297.479 | |||
| ANNX Annexon, Inc. - common stock | $16.833.594 | 2,33% | 2.948.090 | $501.175 | |||
| BCAX Bicara Therapeutics Inc. - Common Stock | $16.341.614 | 2,26% | 550.408 | $5.393.999 | |||
| CDNA CareDx, Inc. - Common Stock | $15.158.295 | 2,09% | 531.870 | $5.925.032 | |||
| CLDX Celldex Therapeutics, Inc. - Common Stock | $14.878.642 | 2,06% | 399.856 | $5.476.580 | Naik ×1 | ||
| CMPX Compass Therapeutics, Inc. - Common Stock | $12.771.670 | 1,76% | 5.831.813 | $4.759.944 | Naik ×1 | ||
| ALKS Alkermes plc - Ordinary Shares | $12.708.931 | 1,76% | 242.560 | $4.132.009 | |||
| Penerbit tidak dikenal (CUSIP: 337185102) | $12.142.199 | 1,68% | 603.489 | Naik ×1 | |||
| PRTA Prothena Corporation plc - Ordinary Shares | $11.191.487 | 1,55% | 1.143.155 | $-555.794 | Turun ×3 | ||
| TVTX Travere Therapeutics, Inc. - Common Stock | $9.517.095 | 1,32% | 167.525 | $2.670.336 | Turun ×1 | ||
| TSHA Taysha Gene Therapies, Inc. - Common Stock | $9.475.311 | 1,31% | 1.391.382 | $3.255.833 | |||
| ACRS Aclaris Therapeutics, Inc. - Common Stock | $8.535.045 | 1,18% | 1.613.430 | $2.484.682 | |||
| AGIO Agios Pharmaceuticals, Inc. - Common Stock | $7.926.733 | 1,10% | 213.601 | $700.611 | |||
| CAPR Capricor Therapeutics, Inc. - Common Stock | $5.532.693 | 0,76% | 229.763 | $-1.452.102 | |||
| ALGN Align Technology, Inc. - Common Stock | $5.294.069 | 0,73% | 31.389 | $-1.823.705 | Turun ×1 | ||
| ORKA Oruka Therapeutics, Inc. - Common Stock | $3.192.573 | 0,44% | 33.546 | $250.309 | Turun ×1 | ||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $3.099.184 | 0,43% | 51.345 | $113.472 | |||
| NBIX Neurocrine Biosciences, Inc. - Common Stock | $3.053.349 | 0,42% | 18.117 | $666.615 | |||
| EW Edwards Lifesciences Corporation Common Stock | $3.043.074 | 0,42% | 33.640 | $349.183 | |||
| STOK Stoke Therapeutics, Inc. - Common Stock | $2.769.126 | 0,38% | 84.631 | $13.541 | |||
| CYTK Cytokinetics, Incorporated - Common Stock | $2.742.692 | 0,38% | 32.195 | $620.720 | |||
| PYXS Pyxis Oncology, Inc. - Common Stock | $2.601.474 | 0,36% | 864.277 | $1.126.129 | Turun ×2 | ||
| EHTH eHealth, Inc. - Common Stock | $2.209.368 | 0,31% | 1.482.797 | $296.560 | |||
| CRSP CRISPR Therapeutics AG - Common Shares | $2.160.057 | 0,30% | 39.605 | $276.047 | |||
| SGMT Sagimet Biosciences Inc. - Series A Common Stock | $1.932.500 | 0,27% | 250.000 | Naik ×1 | |||
| NUVB Nuvation Bio Inc. Class A Common Stock | $1.855.139 | 0,26% | 326.609 | $-327.810 | Turun ×3 | ||
| BNTX BioNTech SE - American Depositary Shares | $1.825.083 | 0,25% | 19.614 | $81.791 | |||
| CMPS COMPASS Pathways Plc - American Depository Shares | $1.635.966 | 0,23% | 115.616 | $996.610 | |||
| HUM Humana Inc. Common Stock | $1.582.922 | 0,22% | 3.985 | $891.963 | |||
| NAMS NewAmsterdam Pharma Company N.V. - Ordinary Shares | $1.503.327 | 0,21% | 44.359 | Naik ×1 | |||
| VSTM Verastem, Inc. - Common Stock | $1.182.997 | 0,16% | 309.685 | $-121.296 | Naik ×1 | ||
| MDGL Madrigal Pharmaceuticals, Inc. - Common Stock | $959.530 | 0,13% | 1.787 | $24.089 | |||
| URGN UroGen Pharma Ltd. - Ordinary Shares | $901.600 | 0,12% | 24.500 | $461.090 | |||
| BCYC Bicycle Therapeutics plc - American Depositary Shares | $856.014 | 0,12% | 201.890 | $-80.756 | |||
| XERS Xeris Biopharma Holdings, Inc. - Common Stock | $826.927 | 0,11% | 104.410 | $221.349 | |||
| ABEO Abeona Therapeutics Inc. - Common Stock | $672.786 | 0,09% | 108.865 | $185.071 | |||
| INSP Inspire Medical Systems, Inc. Common Stock | $391.319 | 0,05% | 8.772 | $-61.141 | |||
| PRQR ProQR Therapeutics N.V. - Ordinary Shares | $351.181 | 0,05% | 188.807 | $45.314 | |||
| ALDX Aldeyra Therapeutics, Inc. - Common Stock | $331.660 | 0,05% | 155.709 | $68.512 | |||
| Tidak ada hasil | |||||||
Kepemilikan dengan keyakinan
Posisi meningkat selama 3+ kuartal berturut-turut.
Jumlah saham dilaporkan dalam pengajuan 13F (tidak disesuaikan split)
Taruhan baru terbesar
Posisi baru dibuka kuartal ini, terbesar diurutkan pertama.
Penggerak teratas (QoQ)
| Sekuritas | Aksi | Saham Δ | Nilai Δ |
|---|---|---|---|
| INSM | Dipangkas | -1K | -$23.8M |
| PTCT | Dipangkas | -3K | +$12.2M |
| MIRM | Beli lebih banyak | +24K | +$10.8M |
| ACAD | Dipangkas | -9K | +$8.5M |
| RARE | Hanya pergerakan harga | +0 | +$7.4M |
| DYN | Dipangkas | -5K | +$6.6M |
| CDNA | Hanya pergerakan harga | +0 | +$5.9M |
| CLDX | Beli lebih banyak | +103K | +$5.5M |
| NVCR | Hanya pergerakan harga | +0 | +$5.4M |
| BCAX | Hanya pergerakan harga | +0 | +$5.4M |
Posisi yang keluar
Termasuk peristiwa perusahaan (merger, delisting) — tidak semua keluar adalah penjualan
Posisi tertutup mencerminkan perubahan pelaporan 13F; bagi manajer indeks, ini sering kali mekanis (penghapusan pencatatan, M&A, penyeimbangan ulang indeks), bukan keputusan aktif.
| Sekuritas | Kuartal | Saham sebelumnya | Nilai sebelumnya | Harga sejak keluar |
|---|---|---|---|---|
| FOLD | 30 Juni 2026 | 1.113.045 | $16.094.631 | Tidak lagi dilacak |
| ALNY | 31 Des. 2025 | 32.320 | $14.737.920 | -42,2% |
| GOSS | 31 Maret 2026 | 4.471.592 | $13.861.935 | -53,3% |
| SRPT | 30 Juni 2025 | 210.258 | $13.418.666 | 14,4% |
| STAA | 30 Sep. 2025 | 791.879 | $13.287.730 | -13,7% |
| RNA | 31 Des. 2025 | 109.831 | $4.785.337 | -81,8% |
| DNLI | 30 Juni 2026 | 234.582 | $4.503.974 | -2,2% |
| SLRN | 30 Juni 2025 | 1.792.895 | $4.428.451 | Tidak lagi dilacak |
| NVRO | 31 Maret 2025 | 750.371 | $2.791.380 | Tidak lagi dilacak |
| VERV | 30 Juni 2025 | 575.817 | $2.631.484 | Tidak lagi dilacak |
| KPTIXXXX | 30 Juni 2025 | 324.032 | $1.211.880 | Tidak lagi dilacak |
| KPTI | 30 Sep. 2025 | 187.911 | $809.896 | -71,8% |
| VYNE | 30 Sep. 2025 | 445.434 | $734.966 | Tidak lagi dilacak |
| JSPR | 31 Maret 2025 | 30.651 | $655.318 | -83,4% |
| ALMS | 30 Sep. 2025 | 143.437 | $430.311 | 468,1% |
| TIL | 30 Juni 2025 | 11.165 | $193.824 | -64,0% |
| RLMD | 30 Juni 2025 | 495.146 | $133.689 | 681,7% |
| GBIO | 31 Maret 2026 | 15.047 | $85.467 | Tidak lagi dilacak |
| AKTX | 31 Maret 2026 | 146.024 | $42.201 | 54,2% |